Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD133+ bone marrow stem cells
- Development stage
- Unknown
- Lead developer
- National Cardiovascular Center Harapan Kita
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Transepicardial Injection, Transseptal Injection
01
Overview
This investigational autologous cell therapy involves the isolation and selection of CD133+ hematopoietic stem cells from a patient's own bone marrow. Developed and studied at the National Cardiovascular Center Harapan Kita Hospital in Indonesia, the therapy is specifically designed for patients with coronary artery disease and heart failure (low ejection fraction) who are undergoing coronary artery bypass graft (CABG) surgery. The cells are administered via transepicardial and transseptal injection during the surgical procedure. The primary mechanism of action is thought to be myocardial regeneration and the promotion of angiogenesis through the increased expression of vascular endothelial growth factor (VEGF) and other paracrine growth factors, which aim to improve myocardial perfusion and cardiac function.
- Other names
- CD133+ bone marrow stem cellsautologous CD133+ hematopoietic stem cellsTransepicardial with Transseptal CD 133+ Implantation
Beyond the preview
Go deeper on autologous CD133+ bone marrow stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD133+ bone marrow stem cells.